Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, December 2015


High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients. Lindahl K1, Hörnfeld E, Ståhle L, Carlsson T, Weiland O, Parke Å, Schvarcz R. Ther Drug Monit. 2015 Dec;37(6):745-50. doi: 10.1097/FTD.0000000000000210.

Daclatasvir Plus Asunaprevir for HCV Genotype 1b Infection in Patients With or Without Compensated Cirrhosis: A Pooled Analysis. Kao JH1, Jensen DM2, Manns MP3, et al. Liver Int. 2015 Dec 18. doi: 10.1111/liv.13049. [Epub ahead of print]

Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study. Tsai HH1, Liou HH1, Muo CH1, Lee CZ1, Yen RF1, Kao CH2. Neurology. 2015 Dec 23. pii: 10.1212/WNL.0000000000002307. [Epub ahead of print]

Glucocorticoid receptors, brain-derived neurotrophic factor, serotonin and dopamine neurotransmission are associated with interferon-induced depression. Udina M1, Navinés R2, Egmond E3, et al. Int J Neuropsychopharmacol. 2015 Dec 30. pii: pyv135. doi: 10.1093/ijnp/pyv135. [Epub ahead of print]

Pharmacokinetics and tolerability of paritaprevir, a direct-acting antiviral agent for HCV treatment, with and without ritonavir in healthy volunteers. Menon RM1, Klein CE2, Podsadecki TJ3, Chiu YL4, Dutta S5, Awni WM6. Br J Clin Pharmacol. 2015 Dec 28. doi: 10.1111/bcp.12873. [Epub ahead of print]

Potent Antiviral Activity of Direct-Acting Antivirals, ABT-493 and ABT-530, With 3-day Monotherapy for Hepatitis C Genotype 1 Infection. Lawitz EJ1, O’Riordan WD2, Asatryan A3, et al. Antimicrob Agents Chemother. 2015 Dec 28. pii: AAC.02264-15. [Epub ahead of print]

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir. Walker DR1, Juday TR1, Manthena SR1, Jing Y1, Sood V1. Clinicoecon Outcomes Res. 2015 Dec 17;7:637-42. doi: 10.2147/CEOR.S87261. eCollection 2015.



Chemokine Receptors CXCR3 and CCR6 and Their Ligands in the Liver and Blood of Patients with Chronic Hepatitis C. Arsent’eva NA1, Semenov AV2,3, Lyubimova NE2, et al. Bull Exp Biol Med. 2015 Dec;160(2):252-5. doi: 10.1007/s10517-015-3142-z. Epub 2015 Dec 3.

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Desombere I1,2, Fafi-Kremer S3,4,5,2, Van Houtte F1,2, et al. Hepatology. 2015 Dec 28. doi: 10.1002/hep.28428. [Epub ahead of print]



CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. Pineda-Tenor D1,2, Jiménez-Sousa MA2, Rallón N3, et al. AIDS Res Hum Retroviruses. 2015 Dec 1. [Epub ahead of print]

 12-Week Treatment with Boceprevir, Peginterferon and Ribavirin for Acute Hepatitis C in HIV infected patients. Hullegie SJ1, Claassen MA2, van den Berk GE3, et al. J Hepatol. 2015 Dec 12. pii: S0168-8278(15)00805-3. doi: 10.1016/j.jhep.2015.12.004. [Epub ahead of print]

CD3(+)CD56(+) Natural Killer-Like T Cells Display Anti-HCV Activity but Are Functionally Impaired in HIV(+) Patients With Acute Hepatitis C. Kokordelis P1, Krämer B, Boesecke C, et al. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):338-46. doi: 10.1097/QAI.0000000000000793.

The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.

Cachay ER1, Wyles D1, Hill L2, et al. Open Forum Infect Dis. 2015 Nov 12;2(4):ofv168. doi: 10.1093/ofid/ofv168. eCollection 2015.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Mussini C1, Lorenzini P2, Puoti M3, et al. PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015.

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. Townsend K1, Meissner EG1,2,3, Sidharthan S3, et al. AIDS Res Hum Retroviruses. 2015 Dec 15. [Epub ahead of print]

Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Bottero J1, Boyd A2, Gozlan J3, et al. Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162. doi: 10.1093/ofid/ofv162. eCollection 2015.



Pan-genotypic hepatitis C virus inhibition by natural products derived from the wild Egyptian artichoke. Elsebai MF1, Koutsoudakis G2, Saludes V2, et al. J Virol. 2015 Dec 9. pii: JVI.02030-15. [Epub ahead of print

A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. Lu NT1,2, Crespi CM3,4, Liu NM1, et al. Phytother Res. 2015 Dec 1. doi: 10.1002/ptr.5518. [Epub ahead of print]




A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study. Southern WN1,2,3, Norton B4,5, Steinman M6,7, DeLuca J8,9, Drainoni ML10, Smith BD11, Litwin AH12,13. BMC Infect Dis. 2015 Dec 1;15(1):553. doi: 10.1186/s12879-015-1283-3.

An evaluation of hepatitis C knowledge and correlations with health belief model constructs among African American “baby boomers”. Rashrash ME1, Maneno MK2, Wutoh AK3, Ettienne EE4, Daftary MB5. J Infect Public Health. 2015 Dec 16. pii: S1876-0341(15)00207-5. doi: 10.1016/j.jiph.2015.11.005. [Epub ahead of print]

Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection. Berg MG1, Lee D2,3, Coller K1, et al. PLoS Pathog. 2015 Dec 11;11(12):e1005325. doi: 10.1371/journal.ppat.1005325. eCollection 2015.

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Sundaram V1, Kowdley KV. Expert Rev Gastroenterol Hepatol. 2016 Jan;10(1):13-20. doi: 10.1586/17474124.2016.1116937. Epub 2015 Dec 2.

New prospects for the treatment and prevention of hepatitis C in children. Ohmer S1, Honegger J. Curr Opin Pediatr. 2015 Dec 24. [Epub ahead of print]



Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Tapper EB1, Catana AM1, Sethi N1, Mansuri D1, Sethi S1, Vong A1, Afdhal NH1. Cancer. 2015 Dec 30. doi: 10.1002/cncr.29855. [Epub ahead of print]

Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. van Meer S1, van Erpecum KJ, Sprengers D, et al. Eur J Gastroenterol Hepatol. 2015 Dec 1. [Epub ahead of print]

Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence. Petsaris O1, Vallet S2, Le Guillou-Guillemette H3, et al. J Clin Virol. 2016 Jan;74:19-25. doi: 10.1016/j.jcv.2015.11.011. Epub 2015 Dec 1.

Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Bucci L1, Garuti F1, Camelli V1, et al. Aliment Pharmacol Ther. 2015 Dec 14. doi: 10.1111/apt.13485. [Epub ahead of print]

High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy. Chen TM1,2, Lin CC3,4, Huang PT5, Wen CF6. Tumour Biol. 2015 Dec 12. [Epub ahead of print]

Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma. Shirabe K1, Sugimachi K2, Harada N3, et al. Anticancer Res. 2015 Dec;35(12):6963-9.


Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)